Core Viewpoint - Baijin Life Sciences (01466.HK) has signed a strategic cooperation framework agreement with Shanghai GuHuan Medical Equipment Co., Ltd. to invest in the latter through equity subscription, aiming to establish direct sales channels for branded medical products [1] Group 1: Investment and Partnership - Baijin will invest in GuHuan Medical to enhance its sales channels for medical products [1] - The cooperation framework agreement is set to expire on December 31, 2026, with provisions for early termination by either party with a 10-day notice [1] Group 2: Management and Expertise - Liang Liang will be appointed as the director of the medical division, responsible for the expansion of medical products [1] - GuHuan Medical has over ten years of experience in the medical product supply chain and holds stakes in more than thirty medical beauty institutions [1] - Liang has extensive experience in the medical beauty industry, covering supply chain, medical institution operations, and investment management [1] Group 3: Strategic Goals - The board believes that the agreement will help the company build a comprehensive market ecosystem for medical products, from research and development to self-owned sales channels [1] - The partnership is expected to stabilize and expand the company's revenue sources [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Baijin Life Science Holdings Limited 佰 金 生 命 科 學 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號： 1466） – 1 – 董事會謹此強調，合作框架協議僅載明北京佰金與谷環醫療的初步合作意向，並 不構成任何協議訂約方的任何實質權利及義務，且有待雙方進一步達成正式協議 及╱或安排，有關協議及╱或安排未必會落實。如有需要，本公司將於適當時候 根據香港聯合交易所有限公司證券上市規則（「上市規則」）的相關規定另行刊發公 告。 股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 佰金生命科學控股有限公司 此乃佰金生命科學控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）作出 之自願公告，旨在讓本公司股東（「股東」）及潛在投資者了解本集團的最新業務發 展情況。 本公 ...

Core Viewpoint - Baijin Life Sciences (01466) announced the issuance of 40 million new shares on November 28, 2025, based on the general authorization approved by shareholders on September 30, 2024 [1] Group 1 - The company will issue a total of 40 million new shares [1] - The issuance is contingent upon shareholder approval received on September 30, 2024 [1] - The scheduled date for the share issuance is November 28, 2025 [1]

Core Viewpoint - Baijin Life Sciences (01466) announced the issuance of 40 million new shares on November 28, 2025, based on the general authorization approved by shareholders on September 30, 2024 [1] Group 1 - The company will issue a total of 40 million new shares [1] - The issuance is contingent upon shareholder approval received on September 30, 2024 [1] - The scheduled date for the share issuance is November 28, 2025 [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佰金生命科學控股有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01466 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | 本月 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 佰金生命科學控股有限公司 呈交日期： 2025年12月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01466 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份 ...

Group 1 - The company, Baijin Life Sciences (01466), announced that the conditions precedent of the subscription agreement have been fulfilled, and completion is expected to be realized by November 28, 2025 [1] - A total of 40 million subscription shares will be issued to the subscribers at a subscription price of HKD 0.48 per share, resulting in total proceeds of HKD 19.2 million [1] - The net proceeds from the subscription are approximately HKD 19.1 million, with 60% allocated for repaying bank loans, other borrowings, and payables, while the remaining 40% will be used for general working capital, including audit and professional fees, salaries, and rent payments [1]

Group 1 - The core point of the article is that Baijin Life Sciences (01466.HK) has completed the conditions precedent of a subscription agreement, with the completion date set for November 28, 2025 [1] - A total of 40 million subscription shares will be issued at a subscription price of HKD 0.48 per share [1] - The total amount raised from the subscription is HKD 19.2 million, with a net amount of approximately HKD 19.1 million after deducting related expenses [1] Group 2 - It is expected that 60% of the net proceeds from the subscription (approximately HKD 11.5 million) will be used to repay bank loans, other borrowings, and other payables [1] - The remaining 40% of the net proceeds (approximately HKD 7.6 million) will be allocated for general operating expenses of the group, including audit and professional fees, salaries, and rent payments [1]

Core Viewpoint - Baijin Life Sciences (01466) has completed the prerequisites for a subscription agreement, with the completion date set for November 28, 2025, and will issue a total of 40 million subscription shares at a price of HKD 0.48 per share [1] Financial Summary - The total amount raised from the subscription is HKD 19.2 million, with a net amount of approximately HKD 19.1 million after expenses [1] - It is expected that 60% of the net proceeds will be used to repay bank loans, other borrowings, and other payables, while the remaining 40% will be allocated for general operating expenses, including audit and professional fees, salaries, and rent payments [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購股份之邀請或要約。 佰 金 生 命 科 學 控 股 有 限 公 司 Baijin Life Science Holdings Limited （於開曼群島註冊成立之有限公司） （股份代號： 1466） 完成根據一般授權發行新股份 茲提述佰金生命科學控股有限公司（「本公司」）日期為2025年9月29日及2025年10 月22日之公告（「該等公告」），內容有關根據一般授權發行新股份。除另有界定者 外，本公告所用詞彙與該等公告所界定者具有相同涵義。 完成認購事項 董事會謹此宣佈，認購協議所載先決條件已獲達成，且完成已於2025年11月28日 落實。於完成後，合共40,000,000股認購股份根據認購協議之條款及條件按認購價 每股認購股份0.48港元配發及發行予認購人。 本公司(i)緊接完成前及(ii)緊隨 ...